GlassScriptPhysician profile
Leonard Ingber
NPI 1376632505
$1,374.95
in general payments reported to CMS, 2019-2025
24 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $80.56 · 2021: $294 · 2022: $220 · 2023: $168 · 2024: $257 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $257.90 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $150.77 | 2019-2022 | |
| Abbvie INC. | $118.00 | 2019-2025 | |
| Janssen Biotech, INC. | $99.41 | 2021-2024 | Stelara, Tremfya |
| Ardelyx, INC. | $90.33 | 2023-2024 | Ibsrela |
| Amarin Pharma, INC. | $84.46 | 2019-2021 | |
| Novo Nordisk INC | $70.67 | 2021-2025 | Wegovy |
| Sanofi Pasteur INC. | $64.05 | 2021-2022 | |
| Celgene Corporation | $61.17 | 2021-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $52.77 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $50.75 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $40.21 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $36.39 | 2021 | |
| Qol Medical, LLC | $26.30 | 2024 | Sucraid |
| Alfasigma USA, INC. | $24.88 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.49 | 2022 | |
| Ironwood Pharmaceuticals, INC | $20.28 | 2021 | |
| Genzyme Corporation | $18.36 | 2023 | |
| Seqirus USA INC | $18.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.20 | 2025 | Farxiga |
| Pfizer INC. | $15.01 | 2023 | |
| Intercept Pharmaceuticals, INC. | $14.88 | 2025 | |
| Redhill Biopharma INC. | $12.48 | 2020 | |
| Allergan, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Ingber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.